Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN17092 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 Mid IV Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 3 High IV Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 5 Higher IV Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 6 Low IV Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 2 Mid SC Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 4 High SC Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 7 Low SC Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Expansion Cohort 1 | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Expansion Cohort 2 | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Expansion Cohort 3 | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Name | Type | Description |
|---|---|---|
| REGN17092 | DRUG | Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol |
| Matching Placebo | DRUG | Single ascending IV or SC administration per the protocol |
Key Inclusion Criteria: 1. Has a SARS-CoV-2 negative test result from a sample collected ≤72 hours prior to randomization as described in the protocol 2. Has received complete primary series of standard-of-care COVID-19 vaccination per local guidance, completed at least 2 weeks prior to screening 3...
REGN17092 is an investigational small molecule drug developed by Regeneron Pharmaceuticals, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers rather than in patients with a specific disease. Regeneron has not disclosed the intended therapeutic indication for REGN17092.
REGN17092 is made by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker REGN. Regeneron is the developer responsible for the compound and for the Phase 1 study conducted in healthy volunteers.
REGN17092 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The study was a randomized, double-blind, controlled trial that enrolled 40 healthy adult volunteers in Belgium.
REGN17092 has been evaluated in one clinical trial, NCT05923424, titled "A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults." The Phase 1 study enrolled 40 participants in Belgium, was randomized, double-blind, and controlled, and has been completed.
REGN17092 is not approved. It is an investigational drug that has completed a single Phase 1 trial in healthy volunteers, which is the earliest stage of clinical testing. No regulatory approval has been granted for REGN17092.
The Phase 1 trial NCT05923424 evaluated different doses of REGN17092 for safety in healthy adults. It enrolled 40 participants aged 18 years and older in Belgium, used a randomized, double-blind, controlled design, and has been completed.